Multi-Agent Chemotherapy Overcomes Glucocorticoid Resistance Conferred by a BIM Deletion Polymorphism in Pediatric Acute Lymphoblastic Leukemia
Table 1
Biological and clinical features of patients from the Ma-Spore ALL 2003 trial genotyped for the BIM polymorphism.